Document Detail


Varenicline use in patients with mental illness: an update of the evidence.
MedLine Citation:
PMID:  20166836     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IMPORTANCE OF THE FIELD: Patients with a psychiatric diagnosis have a higher prevalence of smoking compared to the general population. Varenicline is a first-line pharmacotherapy option to assist in smoking cessation. Clinical trials during drug development excluded patients with active psychiatric illnesses leaving the risks associated with varenicline use in this patient population unknown.
AREAS COVERED IN THIS REVIEW: Literature published in English up to December 2009 were identified and include neuropsychiatric adverse drug events reported in pre-marketing trials and post-marketing surveillance, varenicline case reports, evidence surrounding the use of varenicline in patients with psychiatric diagnoses, and varenicline and suicidality.
WHAT THE READER WILL GAIN: Although the risk of potential neuropsychiatric events is evident through voluntary reporting systems and reported cases in the literature, multiple studies and case reports support the use of varenicline in the mental health population. Reviewing the literature will enable clinicians to optimize patient care by weighing the risks and benefits associated with varenicline use against the risk of continued smoking.
TAKE HOME MESSAGE: Cautious treatment initiation, patient education, and close follow-up, monitoring for mood and behavior changes during therapy are recommended, especially in the psychiatric setting.
Authors:
Tara L Purvis; Leigh Anne Nelson; Scott E Mambourg
Related Documents :
24250856 - A rare case of facioscapulohumeral muscular dystrophy and myasthenia gravis.
8865356 - On background factors of male genital self-mutilation.
24890576 - Guidelines for reporting case studies on extracorporeal treatments in poisonings: metho...
25017776 - Mycotic abdominal aortic aneurysm caused by campylobacter fetus: a case report and lite...
11210906 - Cardiac rupture following blunt trauma.
21487376 - Recurrent pneumococcal meningitis in a child with transethmoidal encephalocele: a case ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  9     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-22     Completed Date:  2010-12-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  471-82     Citation Subset:  IM    
Affiliation:
VA Sierra Nevada Health Care System, Reno, USA. tara.purvis2@va.gov
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Benzazepines / adverse effects,  pharmacology,  therapeutic use*
Evidence-Based Medicine / methods*,  trends*
Humans
Limbic System / drug effects,  physiology
Mental Disorders / chemically induced,  drug therapy,  psychology*
Mood Disorders / chemically induced,  diagnosis,  psychology
Patient Education as Topic / methods
Quinoxalines / adverse effects,  pharmacology,  therapeutic use*
Smoking / psychology*,  therapy
Smoking Cessation / methods*
Suicide / psychology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Benzazepines; 0/Quinoxalines; 0/varenicline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Headache and medication overuse: are clinical case series appropriate to reveal differential risks o...
Next Document:  Delayed-onset and recurrent limb weakness associated with West Nile virus infection.